UOC
RARE icon

UBS O'Connor’s Ultragenyx Pharmaceutical RARE Stock Holding History

UBS O'Connor’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,000
Closed -$238K – 417
2025
Q2 		$238K Buy
+60,000
New +$2.16M 0.01% 291
2024
Q4 		– Sell
-25,000
Closed -$20K – 548
2024
Q3 		$20K Sell
25,000
-15,000
-38% -$764K ﹤0.01% 449
2024
Q2 		$37K Buy
40,000
+29,300
+274% +$1.25M ﹤0.01% 460
2024
Q1 		$61K Buy
10,700
+700
+7% +$33K ﹤0.01% 436
2023
Q4 		$1.25K Sell
10,000
-85,000
-89% -$3.3M ﹤0.01% 496
2023
Q3 		$109K Buy
95,000
+85,000
+850% +$3.37M ﹤0.01% 466
2023
Q2 		$21.3K Buy
+10,000
New +$464K ﹤0.01% 530

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

UBS O'Connor's RARE Position: Q3 2025 in Review

UBS O'Connor sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 31,861 shares — an estimated $1.16M sold.

UBS O'Connor first reported a position in RARE in Q4 2014 and held it in 13 quarters. The position peaked at $3.18M in Q1 2025. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • UBS O'Connor reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 31,861 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $1.16M.
  • UBS O'Connor first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and held it in 13 quarters.
  • UBS O'Connor's Ultragenyx Pharmaceutical position peaked at $3.18M in Q1 2025.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.